Literature DB >> 22242458

Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects.

Yan-ni Teng1, Rui-qian Dong, Ben-jie Wang, Huan-jun Liu, Zhi-mei Jiang, Chun-min Wei, Rui Zhang, Gui-yan Yuan, Xiao-yan Liu, Rui-chen Guo.   

Abstract

The aim of this study is to establish an HPLC method for simultaneous determinations of mifepristone and its metabolites, mono-demethylated mifepristone, di-demethylated mifepristone and C-hydroxylated mifepristone in plasma and to evaluate the pharmacokinetic characteristics of mifepristone tablet. Twenty healthy female Chinese subjects were recruited and a series of blood samples were collected before and after 0.25, 0.5, 1.0, 1.5, 2.0, 4.0, 8.0, 12.0, 24.0, 48.0, 72.0 and 96.0 hours administration by a single oral dose of 75 mg mifepristone tablet. Mifepristone and its three metabolites were extracted from plasma using ethyl acetate and determined by high performance liquid chromatography. The main pharmacokinetic parameters of mifepristone and its metabolites, including Cmax, tmax, MRT, t(1/2), V, CL, AUC(0-96 h) and AUC(0-infinity), were calculated by Drug and Statistical Software Version 2.0. The simple, accurate and stable method allows the sensitive determinations of mifepristone and its metabolites in human plasma up to 4 days after oral administration of 75 mg mifepristone tablet and the clinical applications of their pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22242458

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  2 in total

1.  Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).

Authors:  Jichuang Wang; Jianzhong Chen; Liyuan Wan; Jingwei Shao; Yusheng Lu; Yewei Zhu; Minrui Ou; Suhong Yu; Haijun Chen; Lee Jia
Journal:  AAPS J       Date:  2014-01-18       Impact factor: 4.009

Review 2.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.